Transforming Management of Indolent Systemic Mastocytosis With Precision Medicine - European Medical Journal

Transforming Management of Indolent Systemic Mastocytosis With Precision Medicine

Blueprint Medicines-sponsored symposium from the EAACI Congress 2024


Systemic mastocytosis (SM) is driven by KIT D816V mutation in approximately 95% of cases.1 With the emergence of targeted treatments for indolent systemic mastocytosis (ISM) comes an opportunity to transition from best supportive care to disease-modifying therapy.

At the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Massimo Triggiani (University of Salerno, Italy), Ivan Alavarez-Twose (Virgin del Valle Hospital, Spain), and Frank Siebenhaar (Charité – Universitätsmedizin Berlin, Germany), provided expert insights on improving ISM diagnosis and disease burden assessment, and the emerging impact of precision medicine.

Welcome and introductions

Massimo Triggiani introduces the symposium program and briefly outlines the biology of mast cells, their activating receptors, and their role in ISM pathogenesis, including the impact of KIT D816V mutation

Precision medicine begins with accurate diagnosis: Hallmark symptoms and diagnostic parameters for ISM

Ivan Alvarez-Twose describes the hallmark symptoms of ISM, including those affecting the skin and the gastrointestinal system, bone disease and anaphylaxis, and outlines the diagnostic work-up of ISM

Disease burden in ISM: Using PRO tools to assess the individual patient experience

Frank Siebenhaar describes the symptomatic burden of ISM and shares available patient-reported outcome (PRO) tools for the assessment and ongoing monitoring of patients’ symptoms and quality of life in clinical practice

Symptomatic management of ISM: Are we doing enough?

Ivan Alvarez-Twose shares a stepwise approach for the symptomatic management of ISM

Precision medicine era in ISM: Current and emerging targeted treatments

Frank Siebenhaar provides an update on emerging precision medicines in ISM

Reference:
1. Bose P. and Verstovesek S. Expert Rev Hematol. 2021;14:687–696.

Blueprint Medicines and the associated logo are trademarks of Blueprint Medicines Corporation. © 2024 Blueprint Medicines Corporation.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given